Medicine:Genetic vaccine

From HandWiki
Revision as of 20:40, 5 March 2023 by AnLinks (talk | contribs) (simplify)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

A genetic vaccine (also gene-based vaccine) is a vaccine that contains nucleic acids such as DNA or RNA that lead to protein biosynthesis of antigens within a cell. Genetic vaccines thus include DNA vaccines, RNA vaccines and viral vector vaccines.

Properties

Most vaccines other than live attenuated vaccines and genetic vaccines are not taken up by MHC-I-presenting cells, but act outside of these cells, producing only a strong humoral immune response via antibodies. In the case of intracellular pathogens, an exclusive humoral immune response is ineffective.[1] Genetic vaccines are based on the principle of uptake of a nucleic acid into cells, whereupon a protein is produced according to the nucleic acid template. This protein is usually the immunodominant antigen of the pathogen or a surface protein that enables the formation of neutralizing antibodies that inhibit the infection of cells. Subsequently, the protein is broken down at the proteasome into short fragments (peptides) that are imported into the endoplasmic reticulum via the transporter associated with antigen processing, allowing them to bind to MHCI-molecules that are subsequently secreted to the cell surface. The presentation of the peptides on MHC-I complexes on the cell surface is necessary for a cellular immune response. As a result, genetic vaccines and live vaccines generate cytotoxic T-cells in addition to antibodies in the vaccinated individual. In contrast to live vaccines, only parts of the pathogen are used, which means that a reversion to an infectious pathogen cannot occur as it happened during the polio vaccinations with the Sabin vaccine.[2]

Administration

Genetic vaccines are most commonly administered by injection (intramuscular or subcutaneous) or infusion, and less commonly and for DNA, by gene gun or electroporation. While viral vectors have their own mechanisms to be taken up into cells, DNA and RNA must be introduced into cells via a method of transfection. In humans, the cationic lipids SM-102, ALC-0159 and ALC-0315 are used in conjunction with electrically neutral helper lipids. This allows the nucleic acid to be taken up by endocytosis and then released into the cytosol.

Applications

Examples of genetic vaccines approved for use in humans include the RNA vaccines tozinameran and mRNA-1273, the DNA vaccine ZyCoV-D as well as the viral vectors AZD1222, Ad26.COV2.S, Ad5-nCoV, and Sputnik V. In addition, genetic vaccines are being investigated against proteins of various infectious agents, protein-based toxins,[3] as cancer vaccines,[4] and as tolerogenic vaccines for hyposensitization of type I allergies.[5][6]

History

The first use of a viral vector for vaccination – a Modified Vaccinia Ankara Virus expressing HBsAg – was published by Bernard Moss and colleagues.[7][8] DNA was used as a vaccine by Jeffrey Ulmer and colleagues in 1993.[9] The first use of RNA for vaccination purposes was described in 1993 by Frédéric Martinon, Pierre Meulien and colleagues[10][11] and in 1994 by X. Zhou, Peter Liljeström, and colleagues in mice.[12][11] Martinon demonstrated that a cellular immune response was induced by vaccination with an RNA vaccine.[11] In 1995, Robert Conry and colleagues described that a humoral immune response was also elicited after vaccination with an RNA vaccine.[13][11] While DNA vaccines were more frequently researched in the early years due to their ease of production, low cost, and high stability to degrading enzymes, but sometimes produced low vaccine responses despite containing immunostimulatory CpG sites,[14][15] more research was later conducted on RNA vaccines, whose immunogenicity was often better due to inherent adjuvants and which, unlike DNA vaccines,[16] cannot insert into the genome of the vaccinated. Accordingly, the first RNA- and DNA-based vaccines approved for humans were RNA and DNA vaccines used as COVID vaccines. Viral vectors had previously been approved as ebola vaccines.

References

  1. ↑ Eckhart Buddecke: Molekulare Medizin. ecomed-Storck GmbH, 2002, ISBN 3609160918. S. 162.
  2. ↑ Wolfram Gerlich: Medizinische Virologie. Georg Thieme Verlag, 2010, ISBN 3131139625. S. 466.
  3. ↑ R. G. Pergolizzi, R. Dragos, A. E. Ropper, A. Menez, R. G. Crystal: Protective immunity against alpha-cobratoxin following a single administration of a genetic vaccine encoding a non-toxic cobratoxin variant. In: Human gene therapy. Band 16, Nummer 3, March 2005, S. 292–298, doi:10.1089/hum.2005.16.292, PMID 15812224.
  4. ↑ Freda K. Stevenson, Gianfranco di Genova, Christian H. Ottensmeier, Natalia Savelyeva: Cancer Immunotherapy. Elsevier Inc., 2013, ISBN 0128059117. Kapitel IX: Clinical Trials of DNA vaccines.
  5. ↑ R. Weiss, S. Scheiblhofer, J. Thalhamer: Allergens are not pathogens: why immunization against allergy differs from vaccination against infectious diseases. In: Human vaccines & immunotherapeutics. Band 10, Nummer 3, 2014, S. 703–707, doi:10.4161/hv.27183, PMID 24280693, PMC 4130253.
  6. ↑ R. Weiss, S. Scheiblhofer, J. Thalhamer: Generation and Evaluation of Prophylactic mRNA Vaccines Against Allergy. In: Methods in molecular biology. Band 1499, 2017, S. 123–139, doi:10.1007/978-1-4939-6481-9_7, PMID 27987146.
  7. ↑ G. L. Smith, M. Mackett, B. Moss: Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. In: Nature. Band 302, Nummer 5908, April 1983, S. 490–495, doi:10.1038/302490a0, PMID 6835382.
  8. ↑ C. Y. Yong, H. K. Ong, S. K. Yeap, K. L. Ho, W. S. Tan: Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus. In: Frontiers in Microbiology. Band 10, 2019, S. 1781, doi:10.3389/fmicb.2019.01781, PMID 31428074, PMC 6688523.
  9. ↑ J. B. Ulmer, J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman: Heterologous protection against influenza by injection of DNA encoding a viral protein. In: Science. Band 259, Nummer 5102, March 1993, S. 1745–1749, doi:10.1126/science.8456302, PMID 8456302.
  10. ↑ F. Martinon, S. Krishnan, G. Lenzen, R. Magné, E. Gomard, J. G. Guillet, J. P. Lévy, P. Meulien: Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. In: European journal of immunology. Band 23, Nr. 7, Juli 1993, S. 1719–1722, doi:10.1002/eji.1830230749, PMID 8325342.
  11. ↑ 11.0 11.1 11.2 11.3 Rein Verbeke, Ine Lentacker, Stefaan C. De Smedt, Heleen Dewitte: Three decades of messenger RNA vaccine development. In: Nano Today. 28, 2019, S. 100766, doi:10.1016/j.nantod.2019.100766.
  12. ↑ X. Zhou, P. Berglund, G. Rhodes, S. E. Parker, M. Jondal, P. Liljeström: Self-replicating Semliki Forest virus RNA as recombinant vaccine. In: Vaccine. Band 12, Nr. 16, December 1994, S. 1510–1514, doi:10.1016/0264-410x(94)90074-4, PMID 7879415.
  13. ↑ R. M. Conry, A. F. LoBuglio, M. Wright, L. Sumerel, M. J. Pike, F. Johanning, R. Benjamin, D. Lu, D. T. Curiel: Characterization of a messenger RNA polynucleotide vaccine vector. In: Cancer Research. Band 55, Nummer 7, April 1995, S. 1397–1400, PMID 7882341.
  14. ↑ D. Eusébio, A. R. Neves, D. Costa, S. Biswas, G. Alves, Z. Cui,.. S: Methods to improve the immunogenicity of plasmid DNA vaccines. In: Drug discovery today. June 2021, doi:10.1016/j.drudis.2021.06.008, PMID 34214667.
  15. ↑ L. Li, N. Petrovsky: Molecular mechanisms for enhanced DNA vaccine immunogenicity. In: Expert review of vaccines. Band 15, Nummer 3, 2016, S. 313–329, doi:10.1586/14760584.2016.1124762, PMID 26707950, PMC 4955855.
  16. ↑ Matthias Giese: Molecular Vaccines. Springer Science & Business Media, 2013, ISBN 3319009788. S. 497.




Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Genetic_vaccine&oldid=2554619"